FDA, COVID and vaccine
Digest more
The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels about heart inflammation.
10h
India Today on MSNCovid-19 vaccine rules may change from 2025: What you should knowThe FDA may limit annual COVID-19 boosters to high-risk groups unless clinical trials prove benefits for healthy adults under 65. Pfizer is reviewing the plan, while officials call for more evidence on booster effectiveness.
Historically, almost everyone has been eligible for Covid vaccines; the C.D.C. recommended the most recent vaccine for all Americans over 6 months of age.
Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared to other strains on the rise, but it does have a greater ability to bind to human cells, suggesting it could be more transmissible.
The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr. Philip Dormitzer, may have “conspired to withhold public
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.